A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Multiple Ascending Doses in Young and Elderly Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2012
At a glance
- Drugs AZD 2423 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2010 Planned end date changed from 1 Jul 2010 to 1 May 2010 as reported by ClinicalTrials.gov.
- 20 Apr 2010 Planned number of patients changed from 98 to 74 as reported by ClinicalTrials.gov.